Compare Stocks: ACTU, RFAI, ALDX, and FBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$1.01 +3.6%	$1.49	$0.90 ▼ $9.22	$24.17M	0.78	173,159 shs	109,613 shs
ALDX Aldeyra Therapeutics	$1.56 +8.3%	$1.81	$1.07 ▼ $6.18	$94.12M	1.21	1.95 million shs	829,953 shs
FBIO Fortress Biotech	$2.93 -1.7%	$3.07	$1.97 ▼ $4.53	$97.33M	1.21	716,880 shs	1.03 million shs
RFAI RF Acquisition Corp II	$11.08 +0.0%	$11.06	$10.58 ▼ $11.44	$92.37M	N/A	26,840 shs	2,243 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+0.54%	-20.72%	-43.64%	-62.78%	-88.57%
ALDX Aldeyra Therapeutics	-5.26%	-9.43%	-25.39%	-14.29%	-73.18%
FBIO Fortress Biotech	+8.36%	+7.58%	-20.11%	+23.65%	+54.40%
RFAI RF Acquisition Corp II	+0.05%	-0.14%	+0.05%	+1.05%	+4.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$1.01 +3.6%	$1.49	$0.90 ▼ $9.22	$24.17M	0.78	173,159 shs	109,613 shs
ALDX Aldeyra Therapeutics	$1.56 +8.3%	$1.81	$1.07 ▼ $6.18	$94.12M	1.21	1.95 million shs	829,953 shs
FBIO Fortress Biotech	$2.93 -1.7%	$3.07	$1.97 ▼ $4.53	$97.33M	1.21	716,880 shs	1.03 million shs
RFAI RF Acquisition Corp II	$11.08 +0.0%	$11.06	$10.58 ▼ $11.44	$92.37M	N/A	26,840 shs	2,243 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+0.54%	-20.72%	-43.64%	-62.78%	-88.57%
ALDX Aldeyra Therapeutics	-5.26%	-9.43%	-25.39%	-14.29%	-73.18%
FBIO Fortress Biotech	+8.36%	+7.58%	-20.11%	+23.65%	+54.40%
RFAI RF Acquisition Corp II	+0.05%	-0.14%	+0.05%	+1.05%	+4.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	2.50	Moderate Buy	$13.67	1,253.14% Upside
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	252.56% Upside
FBIO Fortress Biotech	2.25	Hold	$17.00	480.20% Upside
RFAI RF Acquisition Corp II	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACTU, RFAI, ALDX, and FBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/30/2026	ACTU Actuate Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/24/2026	ACTU Actuate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/10/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/20/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/18/2026	FBIO Fortress Biotech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/18/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.34 per share	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.63 per share	N/A
FBIO Fortress Biotech	$66.16M	1.47	N/A	N/A	$2.00 per share	1.47
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$22.23M	-$0.97	N/A	N/A	N/A	N/A	-430.93%	-180.86%	N/A
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	N/A
FBIO Fortress Biotech	$6.82M	$3.17	0.92	N/A	N/A	193.12%	109.66%	45.56%	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ACTU, RFAI, ALDX, and FBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ACTU Actuate Therapeutics	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A
5/14/2026	Q1 2026	ACTU Actuate Therapeutics	-$0.23	-$0.24	-$0.01	-$0.24	N/A	N/A
5/14/2026	Q1 2026	FBIO Fortress Biotech	-$0.22	$2.82	+$3.04	$2.82	$16.34 million	$16.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.80	1.80
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
FBIO Fortress Biotech	0.18	2.86	2.77
RFAI RF Acquisition Corp II	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
ALDX Aldeyra Therapeutics	59.71%
FBIO Fortress Biotech	96.51%
RFAI RF Acquisition Corp II	N/A

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	57.98%
ALDX Aldeyra Therapeutics	11.80%
FBIO Fortress Biotech	28.50%
RFAI RF Acquisition Corp II	39.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	23.93 million	10.05 million	N/A
ALDX Aldeyra Therapeutics	10	60.33 million	53.21 million	Optionable
FBIO Fortress Biotech	170	33.22 million	23.75 million	Optionable
RFAI RF Acquisition Corp II	N/A	8.34 million	5.08 million	N/A

ACTU, RFAI, ALDX, and FBIO Headlines

Recent News About These Companies

RF Acquisition Corp II Shareholders Approve Extension Amendments

August 14 at 7:31 AM | tipranks.com

RF Acquisition Corp II (RFAI) Holds Steady Near Support as SPAC Trading Remains Tepid - Day Trade Opportunities

July 14, 2026 | donanimhaber.comD

HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Go Public on Nasdaq

July 9, 2026 | quiverquant.comQ

Rf Acquisition Corp II

June 29, 2026 | fool.com

RF Acquisition Corp. II Rt

April 15, 2026 | barrons.com

RF Acquisition Corp. II

April 8, 2026 | barrons.com

RF Acquisition Corp III Completes Initial Public Offering of 10 Million Units on Nasdaq

February 18, 2026 | quiverquant.comQ

RF Acquisition Corp III Prices Initial Public Offering of 10 Million Units at $10.00 Each on Nasdaq

February 12, 2026 | quiverquant.comQ

RF Acquisition Corp II Announces Merger with Nanyang Biologics

October 2, 2025 | tipranks.com

RF Acquisition Corp II Audit Committee Resignation

May 21, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACTU, RFAI, ALDX, and FBIO Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$1.01 +0.03 (+3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 +0.01 (+1.49%)

As of 07:34 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Aldeyra Therapeutics NASDAQ:ALDX

$1.56 +0.12 (+8.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 -0.06 (-3.53%)

As of 07:34 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Fortress Biotech NASDAQ:FBIO

$2.93 -0.05 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.00 (+0.17%)

As of 07:34 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

RF Acquisition Corp II NASDAQ:RFAI

$11.08 +0.01 (+0.05%)

As of 04:00 PM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACTU, RFAI, ALDX, and FBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACTU, RFAI, ALDX, and FBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACTU, RFAI, ALDX, and FBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACTU, RFAI, ALDX, and FBIO Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Aldeyra Therapeutics NASDAQ:ALDX

Fortress Biotech NASDAQ:FBIO

RF Acquisition Corp II NASDAQ:RFAI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACTU, RFAI, ALDX, and FBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACTU, RFAI, ALDX, and FBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACTU, RFAI, ALDX, and FBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACTU, RFAI, ALDX, and FBIO Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Aldeyra Therapeutics NASDAQ:ALDX

Fortress Biotech NASDAQ:FBIO

RF Acquisition Corp II NASDAQ:RFAI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools